FDA Form 1572: what it commits your investigator to, and when it needs updating
Analyzes the commitments embedded in FDA Form 1572 per 21 CFR 312.53, designs portfolio-level 1572 maintenance tracking, and evaluates the regulatory risk of outdated investigator information across IND studies.
The form that is not a form
Every RC has filed a 1572. That is not what this lesson is about. The CRC track teaches you what goes on the form, how the investigator signs it, and why the sponsor collects it before the site can begin enrolling. You know all of that.
What the CRC track does not teach -- because it is not a CRC-level concern -- is what happens to the 1572 after the initial filing. Specifically: how do you know when it needs updating? How do you track that across every IND study in the portfolio? And what is the actual regulatory exposure when the information on a signed 1572 no longer reflects reality?
I have watched site audits produce findings that could have been prevented by a single tracking spreadsheet. A sub-investigator leaves the institution in March, but the 1572 is not updated until November -- seven months during which the FDA's records show a person conducting study activities who no longer works there. A new clinical laboratory begins processing specimens in January, but the 1572 still lists only the laboratory that was current at study start. These are not hypothetical failures. They are the most common 1572 deficiencies I encounter, and they are entirely preventable with the right systems.
The 1572 is not a form you file and forget. It is a living regulatory commitment, and at the portfolio level, you are managing dozens of them simultaneously.
What you will learn
By the end of this lesson, you will be able to:
1
Analyze the commitments embedded in FDA Form 1572 per 21 CFR 312.53, and their operational implications for portfolio-level tracking under ICH E6(R3) Sections 2.1, 2.3, and 2.4
2
Design a 1572 maintenance tracking system that identifies every trigger event requiring form revision across the portfolio and generates alerts before the investigator's commitment becomes inaccurate
3
Evaluate the regulatory risk of outdated 1572 information and determine the appropriate urgency of correction based on the nature and severity of the discrepancy
What the 1572 actually commits the investigator to
Let me be direct about something that is frequently misunderstood: the 1572 is not an administrative form. It is a personal commitment by the investigator to the FDA. Per 21 CFR 312.53(c), the investigator agrees -- by signature -- to conduct the study in accordance with the protocol, to protect the rights, safety, and welfare of participants, to comply with all applicable regulatory requirements, and to ensure that an IRB meeting the requirements of 21 CFR Part 56 will review the research. The investigator further commits that the information on the form is accurate.
That last commitment -- accuracy -- is what creates the RC's operational obligation. Every piece of information on the 1572 is a representation to the FDA. When that information changes and the form is not updated, the investigator's representation to the FDA is no longer true.
ICH E6(R3) reinforces this through multiple sections. Section 2.1 establishes the investigator's qualification requirements, while Section 2.3.1 establishes that the investigator retains ultimate responsibility for delegated trial activities. Section 2.2 addresses adequate resources and qualified staff, while Section 2.3 governs delegation of trial-related activities and investigator oversight. Section 2.4 covers communication with the IRB/IEC. The 1572 is the mechanism through which the investigator certifies these commitments to the FDA for IND studies.
And here is the portfolio-level reality: if the investigator holds active 1572s for six IND studies, a single personnel change may require updating six forms. A laboratory change may affect four. The RC who tracks these obligations study-by-study will inevitably miss one.
The 1572 is the investigator's commitment, but its currency is the RC's operational responsibility
The investigator signs the 1572 and bears legal accountability for its accuracy. But the investigator typically does not maintain a tracking system for when 1572 information becomes outdated across multiple studies. That infrastructure falls to the RC. This is a clear example of the distinction between regulatory accountability (the PI's) and operational execution (the RC's) that runs through the entire regulatory coordinator role. Per ICH E6(R3) Section 2.3.1, the investigator may delegate trial-related activities to other persons or parties, but retains the ultimate responsibility and should maintain appropriate oversight. The RC enables the investigator to fulfill a commitment the investigator may not even realize has been triggered.
The seven trigger events that require 1572 revision
Not every change at the site triggers a 1572 update. The RC needs to know precisely which events do, because a tracking system that alerts on irrelevant changes is a tracking system that gets ignored. Based on the information collected on FDA Form 1572 and the requirements of 21 CFR 312.53, I identify seven categories of trigger events.
Analyzing the high-risk triggers
Three of these seven triggers deserve closer analysis because they create the most significant portfolio-level risk.
Sub-investigator changes are, in my experience, the most frequently missed 1572 update. Sub-investigators leave institutions. New fellows rotate through. Visiting faculty join for a study season and depart. Each of these personnel changes should trigger a 1572 review for every IND study on which that individual was listed -- or should be listed. The challenge is that personnel changes often happen without formal notification to the regulatory team. The department announces a departure. The new fellow starts. Nobody thinks to tell the RC until the next monitoring visit, when the CRA asks why the study is being conducted by someone not on the 1572.
The RC's prevention system must include a mechanism for learning about personnel changes proactively, not reactively. This means establishing notification agreements with the department, the principal investigator's administrative team, and -- critically -- the human resources or credentialing office. When a person with sub-investigator privileges leaves the institution, the RC needs to know within days, not months.
Laboratory changes present a different challenge. A site may add a clinical laboratory to its repertoire gradually -- specimens are sent to the new lab for one study, then another, then another. By the time the RC realizes the laboratory is processing specimens for four IND studies, the 1572s for those studies still list only the original lab. The gap is not dramatic -- no alarm bell rings. But the gap is real, and auditors find it.
IRB transitions are, ironically, the least likely to be missed -- because IRB changes are high-visibility events that typically involve the RC directly. But I include them here because the 1572 update during an IRB transition is sometimes deprioritized in the larger operational complexity of the transition itself. Module 4 covered mid-study IRB transitions; the 1572 update should be an explicit step in the transition checklist.
Figure 1: 1572 update decision flowchart — from site change event to urgency-calibrated action
Designing the portfolio-level 1572 tracking system
A 1572 tracking system is not merely a list of forms. It is a cross-referenced matrix that connects three dimensions: studies (which IND studies have active 1572s at the site), personnel (which individuals are listed on which 1572s), and facilities/laboratories (which resources are listed on which forms). When any element in any dimension changes, the system must identify every 1572 affected.
The minimum data architecture for a 1572 tracking matrix includes the following fields for each active 1572: study identifier and IND number, principal investigator name, date of most recent signed 1572, all listed sub-investigators (with dates added), all listed laboratories (with dates added), all listed facilities, IRB of record, and the sponsor contact for 1572 revisions. The matrix should also capture the date of the last currency review -- the date on which someone verified that all information on the 1572 remains accurate.
I recommend two complementary tracking mechanisms. First, an event-driven alert system: when a trigger event occurs (sub-investigator departure, new lab, IRB change), the system generates a task to review and update every affected 1572. Second, a calendar-driven review cycle: a quarterly audit of all active 1572s against current site information, catching any changes that slipped past the event-driven system. The quarterly review is the safety net. The event-driven system is the primary control.
Coordinating 1572 updates with sponsors
The RC does not unilaterally revise a 1572. The sponsor -- or the CRO acting on the sponsor's behalf -- typically provides the updated form for signature or directs the site to update specific sections. The RC's role is to identify that an update is needed, notify the sponsor, obtain the revised form, secure the investigator's signature, and file the updated 1572. Per 21 CFR 312.53(c), the sponsor must obtain a completed Form 1572 from each participating investigator before permitting the investigator to begin participation. The ongoing accuracy obligation is shared: the investigator must report changes, and the sponsor must collect updated forms. The RC operationalizes both sides of this obligation at the site level.
Evaluating the regulatory risk of outdated information
Not all 1572 deficiencies carry equal risk. The RC must be able to triage -- to distinguish between a deficiency that requires immediate correction and one that can be addressed during the next routine update cycle.
The risk evaluation hinges on two questions. First, does the outdated information affect participant safety or data integrity? A sub-investigator who has departed but is still listed on the 1572 is an inaccuracy, but it does not create a safety risk unless study activities are being attributed to that person. A new laboratory processing specimens that is not listed on the 1572, by contrast, breaks the data integrity chain -- the FDA's records do not reflect where specimens are being analyzed.
Second, does the outdated information create a discrepancy that an auditor or inspector would flag as a significant finding? FDA inspectors reviewing 1572 accuracy will assess whether the inaccuracy reflects a systemic failure of oversight or an isolated administrative delay. A single 1572 updated three weeks late looks like a process improvement opportunity. Five 1572s updated seven months late looks like a site that does not maintain its regulatory commitments.
I categorize 1572 deficiencies into three risk tiers. Tier 1 -- critical: the deficiency affects participant safety, data integrity, or involves an individual conducting study activities who is not authorized on the 1572. These require immediate correction, same business day. Tier 2 -- significant: the deficiency represents an inaccuracy that an auditor would flag as a finding, but does not currently affect safety or data integrity. These require correction within two weeks. Tier 3 -- administrative: the deficiency is a minor inaccuracy (address change, updated CV) that should be corrected at the next scheduled update cycle or quarterly review.
1572 deficiency risk tier examples
A new fellow has been performing study assessments for two weeks but is not listed as a sub-investigator on any of the three active 1572s for the studies they are working on. Study activities conducted by an unauthorized individual represent a regulatory violation with potential data integrity implications. The RC must immediately notify the PI, halt the fellow's study activities until the 1572 is updated, contact all affected sponsors to initiate the update process, and document the gap period.
A sub-investigator resigned from the institution six weeks ago. She is no longer conducting study activities, but remains listed on two active 1572s. No study activities are being attributed to her, so there is no immediate safety or integrity concern. However, the 1572 inaccurately represents her as an active member of the research team. The RC should initiate the removal process with both sponsors and update the forms within two weeks.
The investigator's office address has changed due to an institutional reorganization. The research facilities have not moved, and study conduct is unaffected. This is a factual inaccuracy on the 1572 that should be corrected but does not require urgent action. The RC documents the change and flags it for the next quarterly 1572 currency review or the next occasion when the form is being revised for another reason.
The quarterly currency review -- your safety net
Event-driven alerts catch the changes you know about. The quarterly currency review catches the ones you missed.
The process is straightforward. Once per quarter, the RC pulls the current 1572 for every active IND study and compares it, line by line, against current site information. Is the investigator's address current? Are all active sub-investigators listed and all departed sub-investigators removed? Are all current laboratories and facilities listed? Does the IRB information match the current IRB of record?
This review takes time -- in a portfolio of 15 IND studies, it can consume a full day. But the alternative is discovering 1572 deficiencies during a sponsor audit or FDA inspection, when the finding is documented formally and the site's credibility takes a hit that no amount of retroactive correction fully repairs.
The quarterly review also generates useful portfolio intelligence. If the same type of deficiency appears repeatedly -- sub-investigators consistently added late, for instance -- it signals a systemic gap in the notification chain. The review is not merely a correction exercise. It is a diagnostic tool.
Figure 2: The 1572 tracking matrix — cross-referencing studies, personnel, and facilities to identify every affected form when any element changes
When the system fails -- and how to recover
A portfolio-level tracking system is the prevention. But what happens when the RC discovers -- during an audit, a monitoring visit, or the quarterly review -- that multiple 1572s are out of date? The response requires a structured approach: assess the scope of the deficiency, determine the risk tier for each affected form, sequence the corrections by urgency, notify the appropriate sponsors, and implement the systemic fix that prevents recurrence.
The following case study illustrates exactly this scenario.
Check your understanding
1 of 3
The RC discovers that a new sub-investigator -- a cardiology fellow who started three weeks ago -- has been performing protocol-specified cardiac assessments on two IND studies but is not listed on either 1572. Both sponsors are different. What risk tier applies, and what is the immediate action?
Key takeaways
FDA Form 1572 is not a one-time filing -- it is a living commitment by the investigator to the FDA that must reflect current reality across every IND study in the portfolio. The RC manages this currency through two complementary systems: an event-driven alert mechanism that captures trigger events (personnel changes, laboratory additions, IRB transitions, facility changes) as they occur, and a quarterly currency review that catches any changes the event-driven system missed.
Seven categories of trigger events require 1572 revision, but three dominate the RC's operational attention: sub-investigator changes, laboratory changes, and IRB transitions. Of these, sub-investigator departures are the most frequently missed because they often occur without formal notification to the regulatory team.
Not all 1572 deficiencies carry equal risk. The three-tier framework -- critical (same-day correction when an unlisted individual is conducting study activities or an unlisted facility is generating data), significant (correction within two weeks for inaccuracies that do not currently affect safety or integrity), and administrative (next scheduled review for minor factual updates) -- enables the RC to triage deficiencies and allocate correction effort proportionately across a multi-study portfolio.
Regulatory Coordinator
Full course · Regulatory Submissions & Stakeholder Management
FDA Form 1572: what it commits your investigator to, and when it needs updating
Analyzes the commitments embedded in FDA Form 1572 per 21 CFR 312.53, designs portfolio-level 1572 maintenance tracking, and evaluates the regulatory risk of outdated investigator information across IND studies.
The form that is not a form
Every RC has filed a 1572. That is not what this lesson is about. The CRC track teaches you what goes on the form, how the investigator signs it, and why the sponsor collects it before the site can begin enrolling. You know all of that.
What the CRC track does not teach -- because it is not a CRC-level concern -- is what happens to the 1572 after the initial filing. Specifically: how do you know when it needs updating? How do you track that across every IND study in the portfolio? And what is the actual regulatory exposure when the information on a signed 1572 no longer reflects reality?
I have watched site audits produce findings that could have been prevented by a single tracking spreadsheet. A sub-investigator leaves the institution in March, but the 1572 is not updated until November -- seven months during which the FDA's records show a person conducting study activities who no longer works there. A new clinical laboratory begins processing specimens in January, but the 1572 still lists only the laboratory that was current at study start. These are not hypothetical failures. They are the most common 1572 deficiencies I encounter, and they are entirely preventable with the right systems.
The 1572 is not a form you file and forget. It is a living regulatory commitment, and at the portfolio level, you are managing dozens of them simultaneously.
What you will learn
By the end of this lesson, you will be able to:
1
Analyze the commitments embedded in FDA Form 1572 per 21 CFR 312.53, and their operational implications for portfolio-level tracking under ICH E6(R3) Sections 2.1, 2.3, and 2.4
2
Design a 1572 maintenance tracking system that identifies every trigger event requiring form revision across the portfolio and generates alerts before the investigator's commitment becomes inaccurate
3
Evaluate the regulatory risk of outdated 1572 information and determine the appropriate urgency of correction based on the nature and severity of the discrepancy
What the 1572 actually commits the investigator to
Let me be direct about something that is frequently misunderstood: the 1572 is not an administrative form. It is a personal commitment by the investigator to the FDA. Per 21 CFR 312.53(c), the investigator agrees -- by signature -- to conduct the study in accordance with the protocol, to protect the rights, safety, and welfare of participants, to comply with all applicable regulatory requirements, and to ensure that an IRB meeting the requirements of 21 CFR Part 56 will review the research. The investigator further commits that the information on the form is accurate.
That last commitment -- accuracy -- is what creates the RC's operational obligation. Every piece of information on the 1572 is a representation to the FDA. When that information changes and the form is not updated, the investigator's representation to the FDA is no longer true.
ICH E6(R3) reinforces this through multiple sections. Section 2.1 establishes the investigator's qualification requirements, while Section 2.3.1 establishes that the investigator retains ultimate responsibility for delegated trial activities. Section 2.2 addresses adequate resources and qualified staff, while Section 2.3 governs delegation of trial-related activities and investigator oversight. Section 2.4 covers communication with the IRB/IEC. The 1572 is the mechanism through which the investigator certifies these commitments to the FDA for IND studies.
And here is the portfolio-level reality: if the investigator holds active 1572s for six IND studies, a single personnel change may require updating six forms. A laboratory change may affect four. The RC who tracks these obligations study-by-study will inevitably miss one.
The 1572 is the investigator's commitment, but its currency is the RC's operational responsibility
The investigator signs the 1572 and bears legal accountability for its accuracy. But the investigator typically does not maintain a tracking system for when 1572 information becomes outdated across multiple studies. That infrastructure falls to the RC. This is a clear example of the distinction between regulatory accountability (the PI's) and operational execution (the RC's) that runs through the entire regulatory coordinator role. Per ICH E6(R3) Section 2.3.1, the investigator may delegate trial-related activities to other persons or parties, but retains the ultimate responsibility and should maintain appropriate oversight. The RC enables the investigator to fulfill a commitment the investigator may not even realize has been triggered.
The seven trigger events that require 1572 revision
Not every change at the site triggers a 1572 update. The RC needs to know precisely which events do, because a tracking system that alerts on irrelevant changes is a tracking system that gets ignored. Based on the information collected on FDA Form 1572 and the requirements of 21 CFR 312.53, I identify seven categories of trigger events.
Analyzing the high-risk triggers
Three of these seven triggers deserve closer analysis because they create the most significant portfolio-level risk.
Sub-investigator changes are, in my experience, the most frequently missed 1572 update. Sub-investigators leave institutions. New fellows rotate through. Visiting faculty join for a study season and depart. Each of these personnel changes should trigger a 1572 review for every IND study on which that individual was listed -- or should be listed. The challenge is that personnel changes often happen without formal notification to the regulatory team. The department announces a departure. The new fellow starts. Nobody thinks to tell the RC until the next monitoring visit, when the CRA asks why the study is being conducted by someone not on the 1572.
The RC's prevention system must include a mechanism for learning about personnel changes proactively, not reactively. This means establishing notification agreements with the department, the principal investigator's administrative team, and -- critically -- the human resources or credentialing office. When a person with sub-investigator privileges leaves the institution, the RC needs to know within days, not months.
Laboratory changes present a different challenge. A site may add a clinical laboratory to its repertoire gradually -- specimens are sent to the new lab for one study, then another, then another. By the time the RC realizes the laboratory is processing specimens for four IND studies, the 1572s for those studies still list only the original lab. The gap is not dramatic -- no alarm bell rings. But the gap is real, and auditors find it.
IRB transitions are, ironically, the least likely to be missed -- because IRB changes are high-visibility events that typically involve the RC directly. But I include them here because the 1572 update during an IRB transition is sometimes deprioritized in the larger operational complexity of the transition itself. Module 4 covered mid-study IRB transitions; the 1572 update should be an explicit step in the transition checklist.
Figure 1: 1572 update decision flowchart — from site change event to urgency-calibrated action
Designing the portfolio-level 1572 tracking system
A 1572 tracking system is not merely a list of forms. It is a cross-referenced matrix that connects three dimensions: studies (which IND studies have active 1572s at the site), personnel (which individuals are listed on which 1572s), and facilities/laboratories (which resources are listed on which forms). When any element in any dimension changes, the system must identify every 1572 affected.
The minimum data architecture for a 1572 tracking matrix includes the following fields for each active 1572: study identifier and IND number, principal investigator name, date of most recent signed 1572, all listed sub-investigators (with dates added), all listed laboratories (with dates added), all listed facilities, IRB of record, and the sponsor contact for 1572 revisions. The matrix should also capture the date of the last currency review -- the date on which someone verified that all information on the 1572 remains accurate.
I recommend two complementary tracking mechanisms. First, an event-driven alert system: when a trigger event occurs (sub-investigator departure, new lab, IRB change), the system generates a task to review and update every affected 1572. Second, a calendar-driven review cycle: a quarterly audit of all active 1572s against current site information, catching any changes that slipped past the event-driven system. The quarterly review is the safety net. The event-driven system is the primary control.
Coordinating 1572 updates with sponsors
The RC does not unilaterally revise a 1572. The sponsor -- or the CRO acting on the sponsor's behalf -- typically provides the updated form for signature or directs the site to update specific sections. The RC's role is to identify that an update is needed, notify the sponsor, obtain the revised form, secure the investigator's signature, and file the updated 1572. Per 21 CFR 312.53(c), the sponsor must obtain a completed Form 1572 from each participating investigator before permitting the investigator to begin participation. The ongoing accuracy obligation is shared: the investigator must report changes, and the sponsor must collect updated forms. The RC operationalizes both sides of this obligation at the site level.
Evaluating the regulatory risk of outdated information
Not all 1572 deficiencies carry equal risk. The RC must be able to triage -- to distinguish between a deficiency that requires immediate correction and one that can be addressed during the next routine update cycle.
The risk evaluation hinges on two questions. First, does the outdated information affect participant safety or data integrity? A sub-investigator who has departed but is still listed on the 1572 is an inaccuracy, but it does not create a safety risk unless study activities are being attributed to that person. A new laboratory processing specimens that is not listed on the 1572, by contrast, breaks the data integrity chain -- the FDA's records do not reflect where specimens are being analyzed.
Second, does the outdated information create a discrepancy that an auditor or inspector would flag as a significant finding? FDA inspectors reviewing 1572 accuracy will assess whether the inaccuracy reflects a systemic failure of oversight or an isolated administrative delay. A single 1572 updated three weeks late looks like a process improvement opportunity. Five 1572s updated seven months late looks like a site that does not maintain its regulatory commitments.
I categorize 1572 deficiencies into three risk tiers. Tier 1 -- critical: the deficiency affects participant safety, data integrity, or involves an individual conducting study activities who is not authorized on the 1572. These require immediate correction, same business day. Tier 2 -- significant: the deficiency represents an inaccuracy that an auditor would flag as a finding, but does not currently affect safety or data integrity. These require correction within two weeks. Tier 3 -- administrative: the deficiency is a minor inaccuracy (address change, updated CV) that should be corrected at the next scheduled update cycle or quarterly review.
1572 deficiency risk tier examples
A new fellow has been performing study assessments for two weeks but is not listed as a sub-investigator on any of the three active 1572s for the studies they are working on. Study activities conducted by an unauthorized individual represent a regulatory violation with potential data integrity implications. The RC must immediately notify the PI, halt the fellow's study activities until the 1572 is updated, contact all affected sponsors to initiate the update process, and document the gap period.
A sub-investigator resigned from the institution six weeks ago. She is no longer conducting study activities, but remains listed on two active 1572s. No study activities are being attributed to her, so there is no immediate safety or integrity concern. However, the 1572 inaccurately represents her as an active member of the research team. The RC should initiate the removal process with both sponsors and update the forms within two weeks.
The investigator's office address has changed due to an institutional reorganization. The research facilities have not moved, and study conduct is unaffected. This is a factual inaccuracy on the 1572 that should be corrected but does not require urgent action. The RC documents the change and flags it for the next quarterly 1572 currency review or the next occasion when the form is being revised for another reason.
The quarterly currency review -- your safety net
Event-driven alerts catch the changes you know about. The quarterly currency review catches the ones you missed.
The process is straightforward. Once per quarter, the RC pulls the current 1572 for every active IND study and compares it, line by line, against current site information. Is the investigator's address current? Are all active sub-investigators listed and all departed sub-investigators removed? Are all current laboratories and facilities listed? Does the IRB information match the current IRB of record?
This review takes time -- in a portfolio of 15 IND studies, it can consume a full day. But the alternative is discovering 1572 deficiencies during a sponsor audit or FDA inspection, when the finding is documented formally and the site's credibility takes a hit that no amount of retroactive correction fully repairs.
The quarterly review also generates useful portfolio intelligence. If the same type of deficiency appears repeatedly -- sub-investigators consistently added late, for instance -- it signals a systemic gap in the notification chain. The review is not merely a correction exercise. It is a diagnostic tool.
Figure 2: The 1572 tracking matrix — cross-referencing studies, personnel, and facilities to identify every affected form when any element changes
When the system fails -- and how to recover
A portfolio-level tracking system is the prevention. But what happens when the RC discovers -- during an audit, a monitoring visit, or the quarterly review -- that multiple 1572s are out of date? The response requires a structured approach: assess the scope of the deficiency, determine the risk tier for each affected form, sequence the corrections by urgency, notify the appropriate sponsors, and implement the systemic fix that prevents recurrence.
The following case study illustrates exactly this scenario.
Check your understanding
1 of 3
The RC discovers that a new sub-investigator -- a cardiology fellow who started three weeks ago -- has been performing protocol-specified cardiac assessments on two IND studies but is not listed on either 1572. Both sponsors are different. What risk tier applies, and what is the immediate action?
Key takeaways
FDA Form 1572 is not a one-time filing -- it is a living commitment by the investigator to the FDA that must reflect current reality across every IND study in the portfolio. The RC manages this currency through two complementary systems: an event-driven alert mechanism that captures trigger events (personnel changes, laboratory additions, IRB transitions, facility changes) as they occur, and a quarterly currency review that catches any changes the event-driven system missed.
Seven categories of trigger events require 1572 revision, but three dominate the RC's operational attention: sub-investigator changes, laboratory changes, and IRB transitions. Of these, sub-investigator departures are the most frequently missed because they often occur without formal notification to the regulatory team.
Not all 1572 deficiencies carry equal risk. The three-tier framework -- critical (same-day correction when an unlisted individual is conducting study activities or an unlisted facility is generating data), significant (correction within two weeks for inaccuracies that do not currently affect safety or integrity), and administrative (next scheduled review for minor factual updates) -- enables the RC to triage deficiencies and allocate correction effort proportionately across a multi-study portfolio.
Regulatory Coordinator
Full course · Regulatory Submissions & Stakeholder Management
High — activity by unlisted sub-I creates immediate compliance gap
New clinical laboratory or testing facility
Section 8: Labs/facilities
Affects every study using the new lab
High — specimens processed by unlisted lab compromise data integrity chain
Change in IRB of record
Section 7: IRB name/address
Typically affects one study per IRB transition
High — IRB information is a core 1572 commitment
Investigator name or address change
Section 1: Investigator identification
Affects all active 1572s for that PI
Moderate — administrative but still a representation to FDA
New research facility or change of location
Section 5: Research facilities
Affects studies conducted at that facility
High — conduct at unlisted facility is a serious deficiency
Protocol amendment changing the IND number or phase
Section 3: IND number; Section 4: Phase
Typically study-specific
Moderate — usually handled during amendment process
Investigator qualification change
Section 2: Education/training/experience
Rare; affects all active 1572s
Low — but must be documented if material
Case Study
"The audit preparation discovery"
Clinical ResearchIntermediate10-15 minutes
Scenario
Dr. Sarah Chen, a principal investigator at Riverside Medical Center in Columbus, Ohio, manages eight active studies, six of which are IND studies requiring active 1572s. The sponsor of BEACON-1 -- the largest of these studies, a Phase III oncology trial -- has notified the site that a pre-planned sponsor audit will take place in three weeks. The RC begins an audit preparation review of the regulatory files.
During the review, the RC discovers two problems. First, a sub-investigator -- Dr. Patel, a hematology fellow -- completed his fellowship and left the institution four months ago. He remains listed on the 1572s for three of the six active IND studies. He is no longer performing study activities, but his name appears on forms submitted to the FDA as a current member of the research team. Second, the institutional clinical laboratory added a new satellite location three and a half months ago. The site began sending research specimens to the satellite lab within weeks of its opening for two IND studies. The satellite laboratory is not listed on any active 1572.
The challenge:
The RC has three weeks before the BEACON-1 audit. At least four 1572s are outdated -- three for the departed sub-investigator and at minimum two for the unlisted laboratory. How should the RC approach this situation? What is the correction sequence? And what systemic change prevents this from recurring?
Analysis
Risk tier assessment: The departed sub-investigator (Tier 2 -- no active study conduct, but inaccurate representation) should be addressed across all three affected 1572s simultaneously. The missing laboratory is more concerning (potentially Tier 1 -- specimens have been processed at an unlisted facility for over three months, which breaks the data integrity chain for those studies). The laboratory issue must be prioritized.
Correction sequencing: Begin with the two 1572s affected by the missing laboratory. Contact both sponsors immediately, explain the situation, request updated forms, and secure Dr. Chen's signature. Then address the three 1572s listing the departed sub-investigator. Document the timeline of each deficiency -- when the change occurred, when it was discovered, and when the correction was implemented.
Audit preparation context: For BEACON-1, verify whether the satellite laboratory processes specimens for that study. If yes, this becomes the highest-priority correction. If BEACON-1 uses only the original laboratory, the sub-investigator removal is the more relevant finding for audit readiness. Regardless, the RC should prepare a brief summary for the auditor documenting the findings and corrective actions taken.
Systemic prevention design: Implement a notification agreement with the department and HR for all personnel changes affecting research staff. Establish a laboratory change notification protocol with the lab director. Add both checks to the quarterly 1572 currency review. Consider monthly rather than quarterly reviews if the portfolio has frequent personnel turnover.
Enjoyed this preview?
Enroll to access all courses in the Regulatory Coordinator track.
High — activity by unlisted sub-I creates immediate compliance gap
New clinical laboratory or testing facility
Section 8: Labs/facilities
Affects every study using the new lab
High — specimens processed by unlisted lab compromise data integrity chain
Change in IRB of record
Section 7: IRB name/address
Typically affects one study per IRB transition
High — IRB information is a core 1572 commitment
Investigator name or address change
Section 1: Investigator identification
Affects all active 1572s for that PI
Moderate — administrative but still a representation to FDA
New research facility or change of location
Section 5: Research facilities
Affects studies conducted at that facility
High — conduct at unlisted facility is a serious deficiency
Protocol amendment changing the IND number or phase
Section 3: IND number; Section 4: Phase
Typically study-specific
Moderate — usually handled during amendment process
Investigator qualification change
Section 2: Education/training/experience
Rare; affects all active 1572s
Low — but must be documented if material
Case Study
"The audit preparation discovery"
Clinical ResearchIntermediate10-15 minutes
Scenario
Dr. Sarah Chen, a principal investigator at Riverside Medical Center in Columbus, Ohio, manages eight active studies, six of which are IND studies requiring active 1572s. The sponsor of BEACON-1 -- the largest of these studies, a Phase III oncology trial -- has notified the site that a pre-planned sponsor audit will take place in three weeks. The RC begins an audit preparation review of the regulatory files.
During the review, the RC discovers two problems. First, a sub-investigator -- Dr. Patel, a hematology fellow -- completed his fellowship and left the institution four months ago. He remains listed on the 1572s for three of the six active IND studies. He is no longer performing study activities, but his name appears on forms submitted to the FDA as a current member of the research team. Second, the institutional clinical laboratory added a new satellite location three and a half months ago. The site began sending research specimens to the satellite lab within weeks of its opening for two IND studies. The satellite laboratory is not listed on any active 1572.
The challenge:
The RC has three weeks before the BEACON-1 audit. At least four 1572s are outdated -- three for the departed sub-investigator and at minimum two for the unlisted laboratory. How should the RC approach this situation? What is the correction sequence? And what systemic change prevents this from recurring?
Analysis
Risk tier assessment: The departed sub-investigator (Tier 2 -- no active study conduct, but inaccurate representation) should be addressed across all three affected 1572s simultaneously. The missing laboratory is more concerning (potentially Tier 1 -- specimens have been processed at an unlisted facility for over three months, which breaks the data integrity chain for those studies). The laboratory issue must be prioritized.
Correction sequencing: Begin with the two 1572s affected by the missing laboratory. Contact both sponsors immediately, explain the situation, request updated forms, and secure Dr. Chen's signature. Then address the three 1572s listing the departed sub-investigator. Document the timeline of each deficiency -- when the change occurred, when it was discovered, and when the correction was implemented.
Audit preparation context: For BEACON-1, verify whether the satellite laboratory processes specimens for that study. If yes, this becomes the highest-priority correction. If BEACON-1 uses only the original laboratory, the sub-investigator removal is the more relevant finding for audit readiness. Regardless, the RC should prepare a brief summary for the auditor documenting the findings and corrective actions taken.
Systemic prevention design: Implement a notification agreement with the department and HR for all personnel changes affecting research staff. Establish a laboratory change notification protocol with the lab director. Add both checks to the quarterly 1572 currency review. Consider monthly rather than quarterly reviews if the portfolio has frequent personnel turnover.
Enjoyed this preview?
Enroll to access all courses in the Regulatory Coordinator track.
